Ritonavir
- Generic Name
- Ritonavir
- Brand Names
- Kaletra, Norvir, Paxlovid, Viekira Pak, Ritonavir Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C37H48N6O5S2
- CAS Number
- 155213-67-5
- Unique Ingredient Identifier
- O3J8G9O825
- Background
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibi...
- Indication
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
...
- Associated Conditions
- Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 1b, Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06710990
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
STARLITE for Unresectable High-Grade Gliomas
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 24
- Registration Number
- NCT06428045
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06084507
- Locations
- 🇨🇳
The first hospital of Jilin University, Changchun, Jilin, China
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 100
- Registration Number
- NCT05679388
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults With Long COVID.
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Harlan M Krumholz
- Target Recruit Count
- 100
- Registration Number
- NCT05668091
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Paxlovid for Treatment of Long Covid
- Conditions
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 168
- Registration Number
- NCT05576662
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 436
- Registration Number
- NCT05567952
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
🇺🇸Mercury Street Medical Group, PLLC, Butte, Montana, United States
🇺🇸Global Health Clinical Trials, Miami, Florida, United States
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05545319
- Locations
- 🇧🇬
Multiprofile Hospital for Active Treatment - Sveti Nikolay Chudotvoretz, Lom, Montana, Bulgaria
🇧🇬Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases - Haskovo EOOD, Haskovo, Bulgaria
🇧🇬"University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski" EAD, Pleven, Bulgaria
A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT05441215
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
- Conditions
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 157
- Registration Number
- NCT05438602
- Locations
- 🇨🇦
Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇧🇷IBPClin - Instituto Brasil de Pesquisa Clínica, Rio de Janeiro, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.